The Federal Trade Commission has finalized a settlement with CVS Caremark to resolve allegations that the pharmacy benefit manager artificially inflated insulin prices. The agency estimates the agreement will reduce patient out-of-pocket costs by as much as $8.5 billion over the next decade by mandating a restructuring of how the company handles rebates and insulin access.
A System Built on High List Prices
At the heart of the FTC’s complaint is the role of PBMs—the middlemen tasked with negotiating drug prices between manufacturers and insurers. According to the agency’s official announcement, CVS Caremark, alongside Express Scripts and Optum Rx, implemented a “perverse” rebate system.
Regulators allege that these companies favored insulins with higher list prices over cheaper alternatives to maximize their own revenue. By prioritizing expensive drugs, the PBMs allegedly collected larger rebates, which the FTC claims were used to “line their pockets” rather than lowering costs for patients who often pay coinsurance based on a drug’s inflated sticker price.
Mandated Changes to Formulary Management
The settlement forces CVS Caremark to overhaul how it manages drug formularies and processes rebates. Under the terms of the agreement, the company must:
- Reform rebate strategies: CVS Caremark is now required to adjust its negotiations to prevent the exclusion of lower-cost insulin products from its formularies.
- Deliver financial relief: The FTC projects the deal will unlock approximately $4.5 billion in savings directly through pharmacy counter rebates.
- Increase transparency: The company must provide greater clarity to health plans and employers regarding the net costs of medications, ensuring financial incentives do not block patient access to affordable care.
Escalating Federal Oversight of PBM Giants
This settlement marks a sharp escalation in federal oversight of the pharmacy benefit management industry. The FTC is currently pursuing litigation against other industry leaders, including Cigna’s Express Scripts and UnitedHealth Group’s Optum Rx, citing similar anticompetitive rebate practices.
This action follows a multi-year investigation by the commission into the industry’s influence on drug affordability.
Targeting the Barrier to Diabetes Care
For patients, the objective is simple: lower the financial barrier to essential diabetes management. By forcing a shift away from incentives that favor high-list-price drugs, the FTC aims to stop patients from being disproportionately burdened by rebate-driven pricing models.
The real-world impact will now depend on how CVS Caremark adjusts its formulary management in practice. The agency maintains that these structural changes are a necessary step to restore competition and transparency to the prescription drug supply chain.
Worth a look